Qiagen (NYSE:QGEN) Shares Acquired by Natixis Advisors L.P.

Natixis Advisors L.P. raised its position in Qiagen (NYSE:QGEN - Free Report) by 101.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 598,279 shares of the company's stock after purchasing an additional 301,003 shares during the period. Natixis Advisors L.P. owned 0.27% of Qiagen worth $25,983,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in shares of Qiagen by 81.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company's stock worth $245,299,000 after buying an additional 2,709,030 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Qiagen by 33,220.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company's stock worth $58,435,000 after acquiring an additional 1,341,450 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Qiagen by 5.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 22,257,083 shares of the company's stock worth $901,412,000 after acquiring an additional 1,072,923 shares during the last quarter. Jennison Associates LLC increased its stake in Qiagen by 40.9% during the third quarter. Jennison Associates LLC now owns 1,131,808 shares of the company's stock worth $45,838,000 after acquiring an additional 328,291 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Qiagen by 178.3% in the third quarter. Assenagon Asset Management S.A. now owns 503,592 shares of the company's stock valued at $20,405,000 after purchasing an additional 322,607 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Stock Up 0.7 %

QGEN stock traded up $0.30 during midday trading on Friday, hitting $42.98. The company's stock had a trading volume of 1,317,948 shares, compared to its average volume of 1,175,720. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The firm has a 50-day simple moving average of $42.53 and a 200-day simple moving average of $42.78. The company has a quick ratio of 1.62, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $9.81 billion, a P/E ratio of 28.82, a PEG ratio of 3.64 and a beta of 0.42.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm had revenue of $459.00 million during the quarter, compared to analysts' expectations of $453.91 million. During the same period in the previous year, the firm posted $0.53 EPS. Qiagen's revenue for the quarter was down 5.4% on a year-over-year basis. As a group, equities analysts forecast that Qiagen will post 2.09 EPS for the current year.

Analyst Ratings Changes

QGEN has been the subject of a number of recent analyst reports. Stifel Nicolaus cut their price objective on Qiagen from $55.00 to $45.00 and set a "hold" rating for the company in a research report on Wednesday. Morgan Stanley raised shares of Qiagen from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $49.48 to $51.00 in a research note on Friday, February 16th. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, February 8th. Finally, Citigroup dropped their target price on shares of Qiagen from $61.86 to $60.00 and set a "buy" rating for the company in a report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $50.95.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.